UncategorizedRonald T. Raines, PhD, Joins the Stuart Therapeutics Scientific Advisory Board

January 26, 20180

Stuart Therapeutics, a pre-clinical stage company developing advanced ophthalmic therapeutics, today announced that Ronald T. Raines, PhD, the Firmenich Professor of Chemistry at the Massachusetts Institute of Technology (MIT), has joined the company’s Scientific Advisory Board.

Ronald T. Raines, Ph.D., is an Associate Member of the Broad Institute of MIT and Harvard, and an Affiliate of the Koch Institute for Integrative Cancer Research at MIT. From 1989–2017, he was on the faculty at the University of Wisconsin–Madison. Dr. Raines is a leading expert on the chemistry of collagen, which is the most abundant protein in the human body. Using collagen mimetic peptides, he revealed the underlying basis for the structure and stability of collagen. By applying these insights, he created synthetic collagens that are stronger and longer than any found in Nature. His work on collagen has been supported by the NIH and Arthritis Foundation, and has led to numerous awards, including the Ralph F. Hirschmann Award in Peptide Chemistry and Arthur C. Cope Scholar Award from the American Chemical Society, the Vincent du Vigneaud Award and Rao Makineni Lectureship from the American Peptide Society, and the Emil Thomas Kaiser Award from the Protein Society. Dr. Raines is an inventor on over 50 US patents, and provides Stuart Therapeutics with cutting-edge knowledge on the design, synthesis, and utility of collagen mimetic peptides.

“We are thrilled that Dr. Raines has agreed to join our team at Stuart Therapeutics. As the inventor of the technology that forms the core of our synthetic peptide efforts, he will help accelerate our progress and expand our thinking in this important area of research,” said ST’s President and CEO, Eric Schlumpf. “Dr. Raines’ work helps address the treatment of ophthalmic conditions that millions of people suffer from daily.”

About Stuart Therapeutics:

Stuart Therapeutics, established in 2017, is developing advanced ophthalmologic therapeutics based on advanced synthetic peptide technologies. The company, based in Stuart, Florida, is dedicated to the pursuit of therapeutics that solve difficult to treat eye conditions and diseases.

Leave a Reply

Your email address will not be published. Required fields are marked *